Hologic's (HOLX) "Market Perform" Rating Reiterated at Raymond James Financial

Key Points

• Hologic's stock has a "market perform" rating reiterated by Raymond James Financial, while other analysts have mixed opinions, with some raising their price targets significantly.
• The company reported a quarterly earnings per share (EPS) of $1.08, exceeding estimates, with a year-over-year revenue increase of 1.2%.
• CEO Stephen P. Macmillan sold over 138,000 shares of Hologic stock recently, resulting in a decrease in his holdings by approximately 10.08%.

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "market perform" rating restated by stock analysts at Raymond James Financial in a research note issued on Wednesday,Benzinga reports.

Several other analysts also recently weighed in on HOLX. Argus increased their price objective on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $78.00 price objective on shares of Hologic in a research note on Wednesday. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Finally, Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $79.00.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $0.02 during midday trading on Wednesday, hitting $73.97. 4,553,603 shares of the company's stock were exchanged, compared to its average volume of 2,720,524. The company has a market cap of $16.45 billion, a price-to-earnings ratio of 30.69, a PEG ratio of 2.47 and a beta of 0.63. The business's fifty day moving average price is $67.31 and its two-hundred day moving average price is $63.69. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts forecast that Hologic will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business's stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.88% of the company's stock.

Institutional Investors Weigh In On Hologic

Large investors have recently made changes to their positions in the company. United Services Automobile Association bought a new position in shares of Hologic during the 1st quarter valued at approximately $347,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Hologic during the 1st quarter valued at approximately $641,000. Nordea Investment Management AB grew its stake in shares of Hologic by 7.2% during the 2nd quarter. Nordea Investment Management AB now owns 2,587,414 shares of the medical equipment provider's stock valued at $168,674,000 after acquiring an additional 174,828 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of Hologic by 1.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock valued at $1,980,000 after acquiring an additional 528 shares during the period. Finally, Strs Ohio bought a new position in shares of Hologic during the 1st quarter valued at approximately $12,910,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.